This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Caslini, C. Articles by Hess, J. L. Search for Related Content PubMed PubMed Citation Articles by Caslini, C. Articles by Hess, J. L.

Interaction of MLL Amino Terminal Sequences with Menin Is Required for Transformation

¹ Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan; ² Department of Pathology, University of Alabama, Birmingham, Alabama; ³ Laboratory of Biochemistry and Molecular Biology, The Rockefeller University, New York, New York; and ⁴ Department of Genetics, University of Erlangen, Erlangen, Germany

Requests for reprints: Jay L. Hess, Department of Pathology, University of Michigan Medical School, 5240 Medical Science I, 1301 Catherine Avenue, Ann Arbor, MI 48109-0602. Phone: 734-763-6384; Fax: 734-763-4782; E-mail: jayhess{at}med.umich.edu.

Rearrangements of the mixed lineage leukemia gene MLL are associated with aggressive lymphoid and myeloid leukemias. The resulting MLL fusion proteins enforce high-level expression of HOX genes and the HOX cofactor MEIS1, which is pivotal for leukemogenesis. Both wild-type MLL and MLL fusion proteins interact with the tumor suppressor menin and with the Hoxa9 locus in vivo. Here, we show that MLL sequences between amino acids 5 and 44 are required for interaction with menin and for the transformation of hematopoietic progenitors. Blocking the MLL-menin interaction by the expression of a dominant negative inhibitor composed of amino terminal MLL sequences down-regulates Meis1 expression and inhibits cell proliferation, suggesting that targeting this interaction may be an effective therapeutic strategy for leukemias with MLL rearrangements. [Cancer Res 2007;67(15):7275–83]

This article has been cited by other articles:

				R. K. Slany The molecular biology of mixed lineage leukemia Haematologica, July 1, 2009; 94(7): 984 - 993. [Abstract] [Full Text] [PDF]

				M. Liedtke and M. L. Cleary Therapeutic targeting of MLL Blood, June 11, 2009; 113(24): 6061 - 6068. [Abstract] [Full Text] [PDF]

				S. J. Horton, V. Walf-Vorderwulbecke, S. J. Chatters, N. J. Sebire, J. de Boer, and O. Williams Acute myeloid leukemia induced by MLL-ENL is cured by oncogene ablation despite acquisition of complex genetic abnormalities Blood, May 14, 2009; 113(20): 4922 - 4929. [Abstract] [Full Text] [PDF]

				S. Garapaty, C.-F. Xu, P. Trojer, M. A. Mahajan, T. A. Neubert, and H. H. Samuels Identification and Characterization of a Novel Nuclear Protein Complex Involved in Nuclear Hormone Receptor-mediated Gene Regulation J. Biol. Chem., March 20, 2009; 284(12): 7542 - 7552. [Abstract] [Full Text] [PDF]

				I. Maillard, Y.-X. Chen, A. Friedman, Y. Yang, A. T. Tubbs, O. Shestova, W. S. Pear, and X. Hua Menin regulates the function of hematopoietic stem cells and lymphoid progenitors Blood, February 19, 2009; 113(8): 1661 - 1669. [Abstract] [Full Text] [PDF]

				B. Argiropoulos, E. Yung, and R. K. Humphries Unraveling the crucial roles of Meis1 in leukemogenesis and normal hematopoiesis Genes & Dev., November 15, 2007; 21(22): 2845 - 2849. [Full Text] [PDF]

				P. Wong, M. Iwasaki, T. C.P. Somervaille, C. W. E. So, and M. L. Cleary Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential Genes & Dev., November 1, 2007; 21(21): 2762 - 2774. [Abstract] [Full Text] [PDF]